Triple Hair Group Receives EMA Approval to Start Phase III Clinical Trials on its Therapy-07 Prescription Drug in Europe
Corporate
Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has received approval from the European Medicines Agency (EMA), allowing it to move forward with Phase III clinical trials of its flagship prescription product Therapy-07 in Europe. The clinical trial will commence upon notification to the Agency of the completion status of certain cGMP requirements.
“Receiving the EMA approval to start our Phase III trial is a major milestone for Triple Hair and a testament to the quality of the regulatory plan we submitted,” said Jean-Philippe Gravel, President and CEO of Triple Hair. “While we await other regulatory approvals, this latest approval will allow us to further strengthen our capital structure so that we can begin clinical trials in multiple countries.”
The Phase III trials are designed to measure the efficacy of Therapy-07 on hair regrowth in the treatment of androgenic alopecia.
According to a report published by Grand View Research, Inc. alopecia is an underserved global market valued at US$8.8 billion in 2023, and expected to reach US$16 billion by 2030.
About Triple Hair
Triple Hair Group Inc. is a Canadian biotechnology company focused on the development of innovative therapies for androgenic alopecia, a condition affecting hundreds of millions of men and women worldwide.
The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options.
Triple Hair’s lead product candidate, TH07, is a patented prescription topical therapy currently in Phase III clinical development.
For more information, visit the Company’s website, at www.triplehair.ca/investors.
Contact:
Triple Hair Group
Jean-Philippe Gravel
President and CEO
investors@triplehair.ca
